Company profile: Enzymatics
1.1 - Company Overview
Company description
- Provider of independent, ISO 13485:2003 certified OEM enzyme manufacturing, supplying enzymes for PCR (standard and hot-start Taq polymerases), reverse transcriptases, RNA polymerases and ligases, RNA digestion and protection (RNase A and RNase inhibitors), DNA ligation (T4 DNA Ligase), and gene synthesis (assembly of oligodeoxynucleotides).
Products and services
- DNA Ligation: Delivers enzymes that join DNA fragments, including T4 DNA Ligase, constructing contiguous DNA molecules, OEM-manufactured
- Enzymes for PCR: Supplies standard and hot-start Taq polymerases for polymerase chain reactions, enabling DNA amplification, hot-start configuration as technical qualifier
- Reverse Transcriptases: Offers enzymes that synthesize complementary DNA from RNA templates, producing cDNA strands from RNA, ISO 13485:2003-certified
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enzymatics
Jena Bioscience
HQ: Germany
Website
- Description: Provider of biotechnology products, including isothermal amplification and LAMP products for rapid DNA/RNA analysis, ready-to-use lyophilized PCR mixes in 96-well plates, contamination detection controls for food, cell cultures and nucleic acids, RNA/DNA preparation and cleanup kits with magnetic bead options, and click reagents for lipid and posttranslational modification analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jena Bioscience company profile →
NeuMoDx Molecular
HQ: United States
Website
- Description: Provider of molecular diagnostic (MDx) testing solutions for hospital and clinical reference laboratories, including fully automated, continuous random-access analyzers (NeuMoDx 288 and 96) that integrate sample-to-result using proprietary NeuDry reagent technology, plus lysis buffers (3 and 4), an HBV quant test strip, and a GBS assay.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuMoDx Molecular company profile →
NimbleGen
HQ: United States
Website
- Description: Provider of products and services for the life science research market, offering the SeqCap EZ solution-based capture system that enables exome enrichment in a single test tube, SeqCap EZ libraries covering exome designs, gene panels, and custom content, and SeqCap EZ reagents to maximize workflow.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NimbleGen company profile →
Meridian Bioscience
HQ: United States
Website
- Description: Provider of clinical diagnostic test kits, developing, manufacturing, marketing, and distributing assays for gastrointestinal, viral, respiratory, and parasitic infectious diseases, plus bulk antigens and antibodies. Portfolio includes BreathID Smart (H. pylori), Curian, Immunocard STAT!, Premier, Tru, and Merifluor offering rapid immunoassay, enzyme immunoassay, and fluorescent testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meridian Bioscience company profile →
Recombia
HQ: United States
Website
- Description: Provider of synthetic biology and genome engineering solutions, offering yeast strain optimization, metabolic engineering, and microbial strain engineering to enhance industrial fermentation, produce natural products, and support various industrial applications using rationally designed genetic modifications with high precision, efficiency, and throughput.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Recombia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enzymatics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enzymatics
2.2 - Growth funds investing in similar companies to Enzymatics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enzymatics
4.2 - Public trading comparable groups for Enzymatics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →